Neuroblastoma is the most common extracranial pediatric solid tumor, accounting for approximately 15% of pediatric cancer‒related deaths.1 Patients with neuroblastoma are typically allocated into specific risk groups on the basis of a variety of factors such as the disease stage, the patient's age at diagnosis, and amplification of the MYCN gene (MNA).2,3 These risk groups were originally developed to optimize the match between expected disease severity—defined as event-free survival (EFS)...
